No Data
ProQR Therapeutics Initiated With an Outperform at Evercore ISI
ProQR Therapeutics Price Target Announced at $5.00/Share by Evercore ISI Group
Evercore Initiates ProQR Therapeutics(PRQR.US) With Buy Rating, Announces Target Price $5
ProQR Therapeutics Assumed With an Overweight at Cantor Fitzgerald
ProQR Therapeutics Names Hom as CFO, Lopez Lopez as Chief Medical Officer
ProQR Strengthens Leadership With Appointments of CFO and CMO to Support Next Phase of Growth